DeepMed Research

University Health Network

🇨🇦Canada

Country: 🇨🇦Canada

Ownership: Private

Established: 1999-01-01

Employees: 10K

Market Cap: -

Website: http://www.uhn.ca

Clinical Trials

Sorafenib and Erlotinib in Treating Patients With Metastatic or Unresectable Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: erlotinib hydrochloride
Drug: sorafenib tosylate

First Posted Date: 2005-08-04

Last Posted Date: 2015-07-23

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 17

Registration Number: NCT00126620

Locations: 🇨🇦
Princess Margaret Hospital, Toronto, Ontario, Canada
🇨🇦
Margaret and Charles Juravinski Cancer Centre, Hamilton, Ontario, Canada

Vorinostat and Capecitabine in Treating Patients With Metastatic or Unresectable Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: capecitabine
Drug: vorinostat

First Posted Date: 2005-07-21

Last Posted Date: 2015-07-23

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 28

Registration Number: NCT00121277

Locations: 🇨🇦
Ottawa Hospital Regional Cancer Centre - General Campus, Ottawa, Ontario, Canada
🇨🇦
Princess Margaret Hospital, Toronto, Ontario, Canada

Tipifarnib, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia

Phase 1

Completed

Conditions: Leukemia

Interventions: Drug: cytarabine
Drug: daunorubicin hydrochloride
Drug: tipifarnib

First Posted Date: 2005-01-10

Last Posted Date: 2015-07-23

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 24

Registration Number: NCT00101153

Locations: 🇨🇦
McMaster Children's Hospital at Hamilton Health Sciences, Hamilton, Ontario, Canada
🇨🇦
London Regional Cancer Program at London Health Sciences Centre, London, Ontario, Canada

GTI-2040, Docetaxel, and Prednisone in Treating Patients With Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

First Posted Date: 2004-07-12

Last Posted Date: 2021-04-28

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 22

Registration Number: NCT00087165

Locations: 🇨🇦
Ottawa Hospital Regional Cancer Centre - General Campus, Ottawa, Ontario, Canada
🇨🇦
London Regional Cancer Program at London Health Sciences Centre, London, Ontario, Canada
🇨🇦
British Columbia Cancer Agency - Vancouver Cancer Centre, Vancouver, British Columbia, Canada

and more 2 locations

3-AP and Gemcitabine in Treating Patients With Recurrent, Unresectable, or Metastatic Pancreatic Cancer

Phase 2

Completed

Conditions: Pancreatic Cancer

Interventions: Drug: gemcitabine hydrochloride
Drug: triapine

First Posted Date: 2004-03-09

Last Posted Date: 2018-09-14

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 26

Registration Number: NCT00078975

Locations: 🇨🇦
Margaret and Charles Juravinski Cancer Centre, Hamilton, Ontario, Canada
🇨🇦
Ottawa Hospital Regional Cancer Centre - General Campus, Ottawa, Ontario, Canada
🇨🇦
London Regional Cancer Program at London Health Sciences Centre, London, Ontario, Canada

and more 1 locations

EF5 Prior to Surgery or Biopsy in Patients With Breast, Prostate, or Cervical Cancer or High Grade Soft Tissue Sarcoma

Phase 1

Terminated

Conditions: Head and Neck Cancer
Prostate Cancer
Breast Cancer
Cervical Cancer
Sarcoma

First Posted Date: 2003-12-11

Last Posted Date: 2018-02-22

Lead Sponsor: University Health Network, Toronto

Registration Number: NCT00004261

Locations: 🇨🇦
Princess Margaret Hospital, Toronto, Ontario, Canada

UCN-01 and Topotecan in Treating Patients With Recurrent, Persistent, or Progressive Advanced Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Phase 2

Completed

Conditions: Fallopian Tube Cancer
Ovarian Cancer
Primary Peritoneal Cavity Cancer

First Posted Date: 2003-11-06

Last Posted Date: 2015-07-23

Lead Sponsor: University Health Network, Toronto

Registration Number: NCT00072267

Locations: 🇨🇦
Cancer Care Ontario-London Regional Cancer Centre, London, Ontario, Canada
🇨🇦
Margaret and Charles Juravinski Cancer Centre, Hamilton, Ontario, Canada
🇨🇦
Princess Margaret Hospital, Toronto, Ontario, Canada

and more 1 locations

Bortezomib in Treating Patients With Advanced or Metastatic Transitional Cell Cancer of the Bladder, Renal Pelvis, or Ureter

Phase 2

Completed

Conditions: Transitional Cell Cancer of the Renal Pelvis and Ureter
Bladder Cancer

First Posted Date: 2003-08-07

Last Posted Date: 2015-07-23

Lead Sponsor: University Health Network, Toronto

Registration Number: NCT00066352

Locations: 🇨🇦
Margaret and Charles Juravinski Cancer Centre, Hamilton, Ontario, Canada
🇺🇸
Decatur Memorial Hospital Cancer Care Institute, Decatur, Illinois, United States
🇨🇦
Princess Margaret Hospital, Toronto, Ontario, Canada

and more 12 locations

Perifosine in Treating Patients With Advanced Pancreatic Cancer

Phase 2

Completed

Conditions: Pancreatic Cancer

First Posted Date: 2003-02-06

Last Posted Date: 2015-07-23

Lead Sponsor: University Health Network, Toronto

Registration Number: NCT00053924

Locations: 🇨🇦
Princess Margaret Hospital, Toronto, Ontario, Canada
🇨🇦
Margaret and Charles Juravinski Cancer Centre, Hamilton, Ontario, Canada
🇨🇦
Cancer Care Ontario-London Regional Cancer Centre, London, Ontario, Canada

Perifosine in Treating Patients With Recurrent, Refractory, Locally Advanced, or Metastatic Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

First Posted Date: 2003-02-06

Last Posted Date: 2015-07-23

Lead Sponsor: University Health Network, Toronto

Registration Number: NCT00054145

Locations: 🇨🇦
Ottawa Regional Cancer Centre, Ottawa, Ontario, Canada
🇨🇦
Cancer Care Ontario-London Regional Cancer Centre, London, Ontario, Canada
🇨🇦
Margaret and Charles Juravinski Cancer Centre, Hamilton, Ontario, Canada

and more 1 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy